Alnylam Dodges Stock-Drop Suit Over FDA Approval Efforts
Alnylam Pharmaceuticals escaped a stock-drop suit Monday when a federal judge in Massachusetts dismissed investors' claims that the company made misleading statements about the FDA approval prospects for a drug to...To view the full article, register now.
Already a subscriber? Click here to view full article